Elanco Animal Health Stock Price, News & Analysis

Elanco Animal Health (NYSE: ELAN) has announced significant innovation milestones, including two crucial product approvals. The U.S. FDA approved Increxxa™ for treating bovine and swine respiratory diseases, while Health Canada approved Experior™ 50, the first animal health product aimed at reducing ammonia emissions. In Europe, positive progress was made for Credelio Plus Chewable tablets, and Credelio CAT is expected to receive FDA approval soon. These advancements are expected to drive Elanco's growth, with an anticipated $500-$600 million in new product revenues by 2025.

Elanco Animal Health (NYSE: ELAN) will participate in the Cowen 41st Annual Health Care Conference on March 2, 2021, at 2:50 p.m. ET. Jeff Simmons, the president and CEO, will engage in a virtual fireside chat. A live audio webcast will be available on Elanco's investor website, with replay access for 90 days. Elanco is dedicated to innovating products for the health of animals, following a mission of Food and Companionship Enriching Life.

Elanco Animal Health (NYSE: ELAN) will participate in the BofA Securities Animal Health Virtual Summit on February 25, 2021, featuring a fireside chat with CEO Jeff Simmons at 3:30 p.m. ET. A live audio webcast will be accessible on Elanco’s investor website, with a replay available for 90 days. Elanco is dedicated to innovating animal health products for farm animals and pets, supporting the health of animals, people, and the planet.

Elanco Animal Health (NYSE: ELAN) will release its fourth quarter 2020 financial results on February 24, 2021. A conference call will take place at 8:00 a.m. ET to discuss the results with investors, media, and the public. Participants can access the call via a live webcast on Elanco's website. Established nearly 70 years ago, Elanco is a global leader in animal health, focusing on innovating products and services for farm animals and pets, while promoting sustainability and improving animal health.

AgBiome has appointed Dr. Marijn Dekkers as Chairman of the Board, effective January 1, 2021. Dekkers, a former CEO of Bayer AG and Thermo Fisher Scientific, will leverage his extensive experience to guide AgBiome's growth strategies. Notably, AgBiome is focused on developing natural crop protection products through its proprietary GENESIS™ discovery platform, targeting a significant market opportunity valued at 100 billion dollars. The company also collaborates with Elanco Animal Health to create nutritional health solutions for swine.

Elanco Animal Health (NYSE: ELAN) announces that Sarena Lin, executive VP of Transformation and Technology, will leave the company at the end of January. Lin has played a crucial role in integrating Bayer's animal health business, achieving $300 million in synergies ahead of schedule. As Elanco progresses through its Innovation, Productivity, and Portfolio strategy, responsibility for finance and integration will shift to CFO Todd Young. The company anticipates eight product launches in 2021, with one potentially being a blockbuster, alongside targeted cost savings of $100 million.

Elanco Animal Health (NYSE: ELAN) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021. Jeff Simmons, president and CEO, is scheduled to present at 7:30 a.m. ET and will engage with analysts during the session. A live audio webcast will be accessible in the company's investor section, with a replay available for 90 days. Elanco is committed to enhancing animal health and welfare through innovative products and services, aiming to make a positive impact on society.

Elanco Animal Health (NYSE: ELAN) held its Investor Day today, showcasing an enhanced Innovation, Portfolio, Productivity (IPP) strategy aimed at achieving revenue growth targets. CEO Jeff Simmons emphasized planned annual revenue growth of 3%-4% and adjusted EBITDA and EPS growth. Key highlights include eight expected product launches in 2021, projected revenue additions of $80-150 million, and $300 million in synergies from the Bayer acquisition by 2023. The company raised Q4 2020 revenue guidance to $1,040-$1,070 million, and provided 2021 guidance of $4,520-$4,600 million, despite facing a $70-$75 million impact from antitrust divestitures.

Elanco Animal Health has appointed William F. Doyle, alongside Scott Ferguson and Paul Herendeen, to its Board of Directors. This expansion is part of a strategic move to enhance innovation and operational oversight, particularly following the Bayer Animal Health acquisition. The company will also establish a new Innovation, Science and Technology Committee and an independent Advisory Board to bolster R&D efforts. The Finance Committee's role was expanded to focus on operational initiatives and financial oversight, underlining Elanco's commitment to shareholder value creation amidst integration challenges.